According to recently-released research findings, next-generation blood-thinning drug Xarelto may pose additional risk to patients who are already suffering from kidney disease. The study, based on data taken from the Department of Defense electronic medical records system, found that those with existing kidney ailments were significantly more likely to experience... Read more »

The presiding judge in the coordinated Xarelto lawsuit proceedings has issued a case management order stipulating the injury categories into which cases must be grouped to be considered for potential bellwether trials, which are expected to take place in 2017 as part of the multidistrict litigation (MDL 2592) created to manage... Read more »

On December 2, 2015, six additional claimants added their causes of action to the pending multidistrict litigation (MDL) involving the blood-thinning drug Xarelto. Xarelto, which is also known rivaroxaban, is a relatively new blood thinning drug touted to offer patients an increased level of convenience as they treat their underlying... Read more »

The parties involved in the GranuFlo and NaturaLyte multidistrict litigation were scheduled to meet on Friday, Nov. 22. In a status conference before U.S. District Judge Douglas P. Woodlock, both parties were expected to evaluate the proposed start dates for the first two bellwether trials, to see if they’re on-track. The... Read more »

Bayer Healthcare Pharmaceuticals has reported substantial progress during the latest status conference for the multidistrict litigation (MDL) No. 2100 regarding Yaz and Yasmin lawsuits. The status conference took place early in November 2015. It was presided over by U.S. District Judge David R. Herndon of the Southern District of Illinois.... Read more »

The first bellwether trials in multidistrict litigation 2545, which concerns injuries allegedly caused by testosterone replacement therapy, are slated to go to trial by fall of 2016. Court dockets show that more than 2,700 complaints are currently pending against the manufacturers of Testim, Adroderm, Androgel, Axiron and other products that... Read more »

A plaintiff who filed a lawsuit against multiple manufacturers of testosterone therapy products claims use of Testim and Androgel led to his heart attack in 2013. The plaintiff has joined more than 3,000 other plaintiffs with similar allegations. Those lawsuits have been coordinated into multidistrict litigation in Illinois District Court. The plaintiff... Read more »

The U.S. Judicial Panel on Multidistrict Litigation (JPML) issued a transfer order on October 13, 2015 to centralize all federal Zofran claims into a multidistrict litigation (MDL). The MDL is pending in the U.S. District Court for the District of Massachusetts, where it is proceeding under the direction of Judge F.... Read more »

John A. Purvis of Mississippi has filed a wrongful death lawsuit on behalf of the estate of Betty Jo Purvis. The lawsuit lists Fresenius Medical Care Holdings, Inc. as the defendant. Mr. Purvis added his short form complaint to the Granuflo multidistrict litigation (MDL) No. 2428 on September 23, 2015,... Read more »

Four bellwether trials have been scheduled in the ongoing coordinated proceedings underway involving the blood-thinning medication Xarelto. The judge overseeing the coordination has put four trials on the calendar in the first half of 2017, which will provide valuable insight into how subsequent Xarelto lawsuits may be resolved. All of... Read more »